• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

食管小细胞癌和肺小细胞癌的突变背景和克隆结构存在明显差异,提示预后存在差异。

Distinct mutational backgrounds and clonal architectures implicated prognostic discrepancies in small-cell carcinomas of the esophagus and lung.

机构信息

Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.

Department of Pathology, Hebei Cancer Hospital, Shijiazhuang, Hebei, 050200, China.

出版信息

Cell Death Dis. 2021 May 12;12(5):472. doi: 10.1038/s41419-021-03754-0.

DOI:10.1038/s41419-021-03754-0
PMID:33980813
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8115141/
Abstract

Small-cell carcinoma of the esophagus (SCCE) is a rare and aggressive cancer. Although several consistent genomic changes were observed previously between SCCE and small-cell lung cancer (SCLC), detailed mutational landscapes revealing discrepancies in genetic underpinnings of tumorigenesis between these two cancers are scarce, and little attention has been paid to answer whether these genetic alterations were related to the prognosis. Herein by performing whole-exome sequencing of 48 SCCE and 64 SCLC tumor samples, respectively we have shown that the number of driver mutations in SCCE was significantly lower than in SCLC (p = 0.0042). In SCCE, 46% of recurrent driver mutations were clonal, which occurred at an early stage during tumorigenesis, while 16 driver mutations were found clonal in SCLC. NOTCH1/3, PIK3CA, and ATM were specifically clonal in SCCE, while TP53 was clonal in SCLC. The total number of clonal mutations differed between two cancers and presented lower in SCCE compared to SCLC (p = 0.0036). Moreover, overall survival (OS) was shorter in patients with higher numbers of clonal mutations for both cancers. In summary, SCCE showed distinct mutational background and clonal architecture compared with SCLC. Organ-specific clonal events revealed different molecular mechanisms underlying tumorigenesis, tumor development, patients' prognosis, and possible variations in therapeutic outcomes to candidate treatments.

摘要

食管小细胞癌 (SCCE) 是一种罕见且侵袭性强的癌症。虽然此前在 SCCE 和小细胞肺癌 (SCLC) 之间观察到了一些一致的基因组变化,但揭示这两种癌症在肿瘤发生的遗传基础上存在差异的详细突变图谱却很少,而且很少有人关注这些遗传改变是否与预后有关。在此,我们通过对 48 例 SCCE 和 64 例 SCLC 肿瘤样本进行全外显子组测序,结果表明 SCCE 中的驱动突变数量明显低于 SCLC(p=0.0042)。在 SCCE 中,46%的复发性驱动突变是克隆的,这些突变发生在肿瘤发生的早期阶段,而在 SCLC 中发现了 16 个克隆驱动突变。NOTCH1/3、PIK3CA 和 ATM 特异性在 SCCE 中为克隆,而 TP53 在 SCLC 中为克隆。两种癌症的克隆突变总数不同,SCCE 中的突变总数明显低于 SCLC(p=0.0036)。此外,两种癌症的患者中,克隆突变数量越多,总体生存率 (OS) 越短。总之,SCCE 与 SCLC 相比具有明显不同的突变背景和克隆结构。器官特异性的克隆事件揭示了肿瘤发生、肿瘤发展、患者预后以及对候选治疗方法的可能治疗效果的不同分子机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eee/8115141/c44ce794c25f/41419_2021_3754_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eee/8115141/922d7bd6425b/41419_2021_3754_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eee/8115141/89611a7f47b5/41419_2021_3754_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eee/8115141/b04af691614c/41419_2021_3754_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eee/8115141/88490b90e281/41419_2021_3754_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eee/8115141/c44ce794c25f/41419_2021_3754_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eee/8115141/922d7bd6425b/41419_2021_3754_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eee/8115141/89611a7f47b5/41419_2021_3754_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eee/8115141/b04af691614c/41419_2021_3754_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eee/8115141/88490b90e281/41419_2021_3754_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eee/8115141/c44ce794c25f/41419_2021_3754_Fig5_HTML.jpg

相似文献

1
Distinct mutational backgrounds and clonal architectures implicated prognostic discrepancies in small-cell carcinomas of the esophagus and lung.食管小细胞癌和肺小细胞癌的突变背景和克隆结构存在明显差异,提示预后存在差异。
Cell Death Dis. 2021 May 12;12(5):472. doi: 10.1038/s41419-021-03754-0.
2
Genomic based analyses reveal unique mutational profiling and identify prognostic biomarker for overall survival in Chinese small-cell lung cancer.基于基因组的分析揭示了独特的突变特征,并确定了中国小细胞肺癌患者总生存预后的生物标志物。
Jpn J Clin Oncol. 2019 Dec 27;49(12):1143-1150. doi: 10.1093/jjco/hyz131.
3
Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer.小细胞肺癌中肿瘤突变负担和 KIAA1211 突变的预后影响。
Respir Res. 2019 Nov 7;20(1):248. doi: 10.1186/s12931-019-1205-9.
4
Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.基于基因谱分析的大样本量晚期小细胞肺癌患者预后预测。
Lung Cancer. 2018 Dec;126:182-188. doi: 10.1016/j.lungcan.2018.11.014. Epub 2018 Nov 12.
5
Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.联合型小细胞肺癌与非小细胞肺癌不同组织学成分的临床病理与基因组学比较。
Lung Cancer. 2018 Nov;125:282-290. doi: 10.1016/j.lungcan.2018.10.006. Epub 2018 Oct 9.
6
Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features.新型基于 NGS 的靶向重测序基因 panel 对小细胞肺癌的基因突变分析及其与临床特征的关系。
Biomed Res Int. 2021 Apr 5;2021:3609028. doi: 10.1155/2021/3609028. eCollection 2021.
7
Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.中国患者小细胞肺癌的全面基因组分析及其对治疗潜力的影响。
Cancer Med. 2019 Aug;8(9):4338-4347. doi: 10.1002/cam4.2199. Epub 2019 Jun 14.
8
Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort Study.从不吸烟的小细胞肺癌患者的临床和基因组特征:一项回顾性多中心队列研究的结果。
Chest. 2020 Oct;158(4):1723-1733. doi: 10.1016/j.chest.2020.04.068. Epub 2020 May 26.
9
TP53 mutations and MDM2 gene amplification in squamous-cell carcinomas of the esophagus in south Thailand.泰国南部食管癌中TP53突变与MDM2基因扩增
Int J Cancer. 2000 Oct 15;88(2):223-7. doi: 10.1002/1097-0215(20001015)88:2<223::aid-ijc12>3.0.co;2-g.
10
KRAS Exon 3 and PTEN Exon 7 Mutations in Small-cell Lung Cancer.小细胞肺癌中的 KRAS 外显子 3 和 PTEN 外显子 7 突变。
Curr Med Sci. 2019 Jun;39(3):379-384. doi: 10.1007/s11596-019-2046-y. Epub 2019 Jun 17.

引用本文的文献

1
NSE and ProGRP Are Promising Markers for Diagnosis, Efficacy Evaluation, Follow-Up Monitoring, and Prognosis of Small Cell Esophageal Carcinoma.神经元特异性烯醇化酶和胃泌素释放肽前体是小细胞食管癌诊断、疗效评估、随访监测及预后的有前景的标志物。
Thorac Cancer. 2025 Feb;16(4):e70026. doi: 10.1111/1759-7714.70026.
2
Treatment strategies for limited-stage small cell carcinoma of the esophagus: evidence from a Chinese multicenter cohort study and the American SEER database.局限期食管小细胞癌的治疗策略:来自中国多中心队列研究和美国监测、流行病学和最终结果(SEER)数据库的证据
J Thorac Dis. 2024 Nov 30;16(11):7787-7796. doi: 10.21037/jtd-24-1394. Epub 2024 Nov 26.
3

本文引用的文献

1
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.宫颈癌全外显子组测序鉴定出 ERBB2 和 PIK3CA 突变作为联合治疗的靶点。
Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22730-22736. doi: 10.1073/pnas.1911385116. Epub 2019 Oct 17.
2
Clonal evolution of esophageal squamous cell carcinoma from normal mucosa to primary tumor and metastases.食管鳞癌从正常黏膜到原发肿瘤和转移灶的克隆进化。
Carcinogenesis. 2019 Dec 31;40(12):1445-1451. doi: 10.1093/carcin/bgz162.
3
Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets.
乳腺导管癌的蛋白质基因组图谱揭示肿瘤进展特征和治疗靶点。
Adv Sci (Weinh). 2024 Dec;11(46):e2401041. doi: 10.1002/advs.202401041. Epub 2024 Oct 17.
4
Prognostic factors and treatment strategies of limited-stage primary esophageal small-cell carcinoma-a SEER database analysis.局限期原发性食管小细胞癌的预后因素及治疗策略——一项监测、流行病学和最终结果(SEER)数据库分析
Transl Cancer Res. 2024 Jul 31;13(7):3242-3250. doi: 10.21037/tcr-24-311. Epub 2024 Jul 26.
肿瘤蛋白 p53 和共济失调毛细血管扩张突变与非小细胞肺癌患者免疫检查点抑制剂反应和死亡率的关联。
JAMA Netw Open. 2019 Sep 4;2(9):e1911895. doi: 10.1001/jamanetworkopen.2019.11895.
4
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.PIK3CA 或 AKT 突变和/或 PTEN 缺失/PTEN 突变的晚期乳腺癌患者中 AKT 抑制剂 MK-2206 的 II 期临床试验。
Breast Cancer Res. 2019 Jul 5;21(1):78. doi: 10.1186/s13058-019-1154-8.
5
Association of Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.免疫检查点抑制剂治疗的黑色素瘤和非小细胞肺癌患者的突变与肿瘤突变负荷及预后的关系。
Front Immunol. 2019 May 21;10:1113. doi: 10.3389/fimmu.2019.01113. eCollection 2019.
6
Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer.LRP1B的体细胞突变与肺癌患者的肿瘤突变负担相关。
Lung Cancer. 2019 Jun;132:154-156. doi: 10.1016/j.lungcan.2019.04.025. Epub 2019 Apr 28.
7
Targeting PI3K in cancer: mechanisms and advances in clinical trials.针对癌症的 PI3K 靶向治疗:机制与临床试验进展。
Mol Cancer. 2019 Feb 19;18(1):26. doi: 10.1186/s12943-019-0954-x.
8
Comprehensive Characterization of Cancer Driver Genes and Mutations.癌症驱动基因与突变的全面表征
Cell. 2018 Aug 9;174(4):1034-1035. doi: 10.1016/j.cell.2018.07.034.
9
Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.抑制 Notch1 通过防止 Notch1 依赖性免疫抑制特性增强黑色素瘤的免疫治疗效果。
Cancer Lett. 2018 Oct 10;434:144-151. doi: 10.1016/j.canlet.2018.07.024. Epub 2018 Jul 21.
10
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer.PIK3CA 突变使结直肠癌对一线化疗产生耐药性。
Cell Death Dis. 2018 Jul 3;9(7):739. doi: 10.1038/s41419-018-0776-6.